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Abstract
Mutations in cartilage oligomeric matrix protein (COMP), a large extracellular glycoprotein expressed in musculoskeletal
tissues, cause two skeletal dysplasias, pseudoachondroplasia and multiple epiphyseal dysplasia. These mutations lead to
massive intracellular retention of COMP, chondrocyte death and loss of growth plate chondrocytes that are necessary for
linear growth. In contrast, COMP null mice have only minor growth plate abnormalities, normal growth and longevity. This
suggests that reducing mutant and wild-type COMP expression in chondrocytes may prevent the toxic cellular phenotype
causing the skeletal dysplasias. We tested this hypothesis using RNA interference to reduce steady state levels of COMP
mRNA. A panel of shRNAs directed against COMP was tested. One shRNA (3B) reduced endogenous and recombinant COMP
mRNA dramatically, regardless of expression levels. The activity of the shRNA against COMP mRNA was maintained for up to
10 weeks. We also demonstrate that this treatment reduced ER stress. Moreover, we show that reducing steady state levels
of COMP mRNA alleviates intracellular retention of other extracellular matrix proteins associated with the pseudoachon-
droplasia cellular pathology. These findings are a proof of principle and the foundation for the development of a
therapeutic intervention based on reduction of COMP expression.
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Introduction
Cartilage oligomeric matrix protein (COMP), also known as
thrombospondin 5 (TSP-5), is a low abundance glycoprotein that
is found in the extracellular matrix (ECM) of cartilage, tendon,
ligament and smooth muscle [1,2,3]. Serum and synovial levels of
COMP are now used to assess cartilage erosion in osteoarthritis
and joint injury [4,5]. Interest in this extracellular matrix protein
increased when it was recognized that mutations in COMP caused
pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia
(MED/EDM1) [6,7]. It had long been recognized that both
PSACH and MED chondrocytes retained lamellar appearing
material in large rough endoplasmic reticulum (rER) cisternae [8].
This material was subsequently shown to be composed of COMP
and other ECM proteins including types II and IX collagens and
matrilin-3 (MATN3) [9,10]. Recently, using flouresence deconvo-
lution analysis, these retained proteins were shown to be organized
into a matrix network suggesting that the stalled mutant COMP
inappropriately interacts intracellularly with matrix protein
partners [9,10,11]. The massive retention of intracellular matrix
is toxic to the chondrocytes and prolonged rER stress induces
apoptosis causing chondrocyte death [12]. The resulting loss of
chondrocytes in the growth plate translates into decreased long
bone growth and the disproportionate short stature found in
PSACH. Intracellular retention and death of chondrocytes causes
the loss of these proteins in the ECM [13,14]. The resulting
downstream effect is a disorganized type II collagen network most
likely due to the absence of type IX collagen which is needed to
crosslink type II collagen [15]. Altogether, the loss of these proteins
from the matrix and the poorly organized ECM structure of the
articular cartilage contribute to joint abnormalities and early onset
osteoarthritis characteristic of both PSACH and MED/EDM1
[14,16].
In contrast, COMP knock-out mice are normal in all growth
parameters with only mild growth plate disturbances and
flattening of the articular cartilage surface only found with exercise
[16]. This suggests that the presence of mutant COMP has a
greater negative impact on skeletal growth and development than
the absence of normal COMP. Moreover, these findings also
suggest that surpressing intracellular retention of mutant COMP
by reducing COMP expression could be used as a therapeutic
approach. RNA interference (RNAi) technology is one method to
selectively reduce expression of a particular gene.
The challenges to using RNAi therapy in a clinical setting are
significant and this barrier is particularly difficult with avascular
tissues such as cartilage. Preventing or reducing PSACH cellular
pathology will require long-term reduction of COMP expression
because chondrocytes produce COMP throughout life [2,17,18].
However, there is active research to develop technologies capable
of delivering therapeutics including shRNA delivery vectors to
cartilage tissue. One system relies upon cell-specific antibodies
to attach to viral envelope proteins for specific delivery or
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nanoparticles to deliver plasmids or siRNAs [19,20,21]. Similarly,
polypeptide ligands that bind to cartilage are designed for delivery
into this difficult tissue (US Patent 7592009). Additionally, topical
administration of siRNAs have been shown to deliver sufficient
levels of antisense RNAs to reduce the target mRNA in mice
joints. Osteopontin siRNA cream prevents severe and irreversible
damage to bone and cartilage caused by collagen antibody-
induced rheumatoid arthritis in a mouse model [22]. This topical
delivery method has not been verified in larger animals where
thicker tissue may inhibit sufficient penetration. If this type of
therapy is effective in larger animals then it could be used
for extended periods due to the non-invasive patient-friendly
characteristics of topical applications.
In this study, recombinant lentiviruses encoding the elements
necessary for expression of a COMP-specific shRNA were used
to provide a continuous supply of shRNA for COMP-specific
siRNA duplexes [23]. Three cell types, COS-7, primary human
chondrocytes and rat chondrosarcoma (RCS) cells, were used to
assay the effectiveness of various COMP-directed shRNAs. COS-7
cells were used to screen and assess the ability of individual
shRNAs to reduce COMP expression. Primary human chondro-
cytes were used to demonstrate the effectiveness of shRNA against
endogenously expressed COMP. RCS cells were used to assess the
effect of shRNA targeted against human COMP in the presence
of other ECM proteins. The results presented here indicate that
shRNA directed at COMP reduces expression levels and the
cellular phenotypes of rER retention, indicating potential
therapeutic utility.
Results
Identification of shRNAs that reduce COMP expression
A panel of four shRNAs with predicted homology to different
regions of the human COMP mRNA was screened for the ability
to reduce COMP expression. Stable integrants of each U6-
shRNA expression cassette in COS-7 cells shown in Fig. 1 were
isolated and cultured as described in Material and Methods
section. COS-7 cells with different shRNA integrants were
infected with either wild-type (WT)- or mutant (MT)-COMP
(D469del common mutation) adenovirus and assessed for COMP
knockdown. As shown in Fig. 2, COMP mRNA (A and B) and
protein (C and D) were markedly reduced by two shRNAs, 3A
and 3B, that target different COMP type 3 calcium-repeat
domain sequences (Fig. 1). Two shRNA integrants of 3B (3B-1
and 3B-2) reduced COMP mRNA and protein levels to less than
10% of the control compared to integrants of shRNA 3A (3A A–I)
that only reduced COMP to approximately 30% of the control. In
contrast, the integrants containing GA and GB shRNAs that
target globular domain sequences did not reduce steady state WT-
or MT-COMP mRNA or protein levels (Fig. 2 and data not
shown). These results demonstrate that targeting the type 3 repeat
domain was more effective at reducing COMP than targeting the
globular domain.
shRNA 3B reduces ER stress
Previously, we had shown that calreticulin (CRT), a resident
rER protein, was associated with retained mutant COMP in the
rER of PSACH growth plate chondrocytes [24]. In these
experiments, we sought to determine if reduction of COMP
mRNA by shRNA would reduce ER stress by assessing CRT as a
measure of ER stress in COS-7 cells. Expression of MT-COMP
in the absence of shRNA 3B elevates CRT levels, indicating
increased ER stress (Fig. 3F). Additionally, CRT and MT-COMP
co-localize to the ER, demonstrating intracellular retention
(Fig. 3H). Alternatively, increased ER stress (CRT levels) and
co-localization of CRT and COMP were greatly diminished in
cells overexpressing MT-COMP in the presence of shRNA 3B
(Fig. 3I–L). As expected, shRNA 3B was effective at knocking
down both WT- and MT-COMP because it was not specifically
designed against the mutant COMP mRNA (Fig. 3 and data not
shown). These results suggest that reducing intracellular COMP
via knock down of COMP mRNA lessens ER stress.
shRNAs maintain long-term knock down in the presence
of high levels of COMP expression
Rescue of the PSACH cellular pathology will require long-term
knock down because chondrocytes produce COMP during
growth, development and adulthood [2,17,18,25,26,27,28]. In
these experiments, the ability of shRNA 3A and 3B to knock down
COMP over extended culture time was assessed. COS-7 cells with
and without an shRNA integrant were infected with MT- or WT-
COMP adenovirus, cell lysates were collected 2, 4, 7, and 14 days
post-infection and assayed by Western analysis. The experiment
was terminated after two weeks because COS-7 replication and
viral degradation diluted the adenoviral COMP expression to very
low levels. By 2 days shRNA 3B reduced COMP protein levels by
90%, and COMP expression was not detectable after 4 days of
culture (Fig. 4*) (only MT-COMP results are shown in Fig. 4
because WT-COMP knock down was identical). shRNA 3A was
approximately three times less efficient than 3B at reducing
COMP protein levels. However, this shRNA retained the ability to
reduce COMP expression over time (Fig. 4 A and B).
We next asked if shRNA 3B would be effective against high
levels of COMP expression. In this set of experiments, we used the
tetracycline induced MT-COMP adenovirus and varied the dose
of doxycycline (DOX) to attain high levels of COMP expression.
As can been seen in Fig. 5A, MT-COMP was induced in a dose
dependent manner and high levels were attained at 1 and 10 mg/
ml of DOX. In the presence of shRNA 3B, MT-COMP protein
levels were dramatically reduced (Fig. 5B). Similar results were
found for WT-COMP (data not shown). All together we show
RNAi was effective at reducing high levels of COMP and remains
effective over time.
shRNAs efficiently reduce endogenous COMP expression
in human growth plate chondrocytes
We next tested the efficacy of shRNAs to reduce endogenous
COMP mRNA levels in human chondrocytes. Chondrocytes
Figure 1. Schematic of human COMP showing shRNA target
locations relative to mRNA structure and protein domains.
Solid gray blocks are used to indicate the 59UTR, coding region and
39UTR of COMP mRNA. The positions of COMP protein domains
including the pentamer, epithelial growth factor (EGF)-like, type 3
calcium repeat and globular domains are shown below the protein
structure. The position of the common D469del mutation in exon 17B is
designated by arrow. Stem-loop hairpins indicate target positions of the
shRNAs.
doi:10.1371/journal.pone.0010302.g001
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containing shRNA integrants directed against COMP were grown
in monolayer for one week. As shown in shown in Fig. 6, all four
of the shRNAs reduced endogenous human COMP mRNA levels
by at least 80%. Consistent with our recombinant COMP
expression results, shRNA 3B was the most effective at reducing
endogenous COMP mRNA levels, a 99% reduction. COMP is
Figure 2. shRNAs directed against human COMP effectively reduce steady-state levels of COMP mRNA and protein. COS-7 cells were
stably transfected with shRNAs directed against COMP, and individual clones identified and selected as described in Methods section. Cells were
infected with an adenovirus expressing MT-COMP and collected 48 hours after infection. RNA and protein were purified for subsequent analysis. (A)
Northern blot analysis of steady-state COMP mRNA in transfected cells. (B) Quantification of mRNA in a. Absence of a shRNA was set to 100% and all
other lanes were compared to the no shRNA reference sample. snU6 mRNA was used to normalize protein loading. (C) Western blot analysis. (D)
Quantification of protein in c in which the level of COMP protein from COS-7 cells expressing recombinant COMP protein in the absence of a shRNA
was set to 100% and all other protein levels were compared to this reference. b-actin was used to control for protein loading. All experiments were
replicated at least three times.
doi:10.1371/journal.pone.0010302.g002
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expressed at low levels when human primary chondrocytes are
cultured in monolayer. In this context, all of the shRNAs directed
at COMP work well; however, when COMP expression levels are
higher, shRNA 3B out performs the other shRNAs. This result
shows that shRNA 3B was equally effective at reducing a wide
range of COMP mRNA expression levels.
Figure 3. Cells expressing MT-COMPwith a COMP-directed shRNA 3B show reduction of intracellular COMP and CRT. COS-7 cells with
(I–L) and without (E–H) shRNA 3B were infected with adenoviruses expressing MT-COMP (E–L). Uninfected COS-7 cells with shRNA 3B serves as
controls (A–D). Cells were grown on coverslips for 48 hours after adenoviral infection and immunostained with COMP and CRT antibodies as
described in the Methods section. DAPI (blue) staining was used to localize all of the cells in the field. COMP (green in E) co-localizes (merge-yellow in
H) with CRT (red in F).
doi:10.1371/journal.pone.0010302.g003
Figure 4. Long-term activity of shRNA COMP knockdown was maintained over 2 weeks. COS-7 cells with shRNA 3B, 3A-A or 3A–C
integrant were infected with an adenovirus expressing MT-COMP and protein lysate was collected at 2, 4, 7 and 14 days. (A) Western analysis of
protein lysates of MT-COMP expression levels at 2, 4 and 7 days. After 14 days, appreciable amounts of COMP were not being produced (*). (B)
Quantification of COMP protein levels from COS-7 cells expressing recombinant COMP in the absence of a shRNA was set to 100% (*a) and all other
lanes were compared to this reference. Levels of b-actin were used to normalize protein loading.
doi:10.1371/journal.pone.0010302.g004
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shRNA 3B is effective in reducing intracellular retention
of MT-COMP and other ECM proteins
We have previously shown that MT-COMP expression induces
the intracellular retention of ECM proteins and formation of
intracellular matrix [9,10]. The goal of these studies was to
determine if reduction in MT-COMP synthesis by the most
effective shRNA (3B) can prevent and/or eliminate intracellular
retention of COMP and other ECM proteins. RCS cells were used
in this set of experiments because unlike primary chondrocytes in
monolayer that become fibroblastic and do not synthesize matrix
proteins, RCS cells maintain a chondrocyte phenotype synthesiz-
ing COMP and other ECM proteins [29]. RCS cells with and
without shRNA 3B were infected with adenovirus expressing
FLAG tagged MT-COMP with and green fluorescent protein
(GFP) and fixed after 4 days in culture. DAPI was used to define
the total number of cells and GFP was used to identify infected
cells. Only infected cells were considered in this analysis because
the shRNA targets the human COMP transcript and does not
cross-react with rat COMP. As shown in Fig. 7 (left panel), in
the presence of MT-COMP, MATN3, types IX and II collagens
were co-retained. In comparison, shRNA 3B reduction of MT-
COMP also reduced the retention of other ECM proteins retained
(Fig. 7 right panel). This result demonstrates that reduction of
intracellular MT-COMP by RNAi normalizes the export of the
other matrix proteins preventing the premature protein interac-
tions and intracellular matrix assembly. Moreover, expression of
CRT was also reduced in cells expressing shRNA 3B. These
findings are consistent with the COS-7 results shown in Fig. 3.
Discussion
PSACH is a severe dwarfing condition caused by mutations in
COMP that specifically affects growth plate chondrocytes. These
mutations interfere with protein folding which initiates the ER
stress response causing retention of COMP and other ECM
proteins that assemble prematurely into ordered intracellular
matrix [9,10,11,13,14]. The massive intracellular retention of this
matrix network causes chondrocyte death and results in dimin-
ished limb growth and joint abnormalities. The objective of this
study was to determine whether suppression/reduction of COMP
expression could resolve the cellular chondrocyte pathology. We
show that COMP mRNA and protein levels can be significantly
decreased by shRNAs directed against the COMP type 3 repeat
domain. Specifically, shRNA 3B was effective at reducing
endogenous and recombinant COMP expression and maintaining
this reduction for up to ten weeks (data not shown). The shRNA-
mediated reduction of MT-COMP expression prevented the
development of the PSACH cellular phenotype as demonstrated
by the absence of retained COMP and other ECM proteins. This
is the first study to show that the PSACH cellular phenotype can
be mitigated by RNAi reduction of COMP expression.
Most of the mutations that cause PSACH are in the calcium-
binding domain of COMP [6,30,31,32,33,34]. These mutations
cause increased ER stress, reduced calcium binding, interfere with
calcium-dependant protein folding and hamper protein trafficking
in vitro [13,18,24,35,36]. COMP is a pentameric protein comprised
of five identical monomers assembled in the rER, modified in the
Golgi and then exported to the matrix where it is incorporated
into the extracellular matrix of the growth plate [1]. COMP
mutations have a dominant negative effect because perturbation of
the three dimensional structure of the protein activates the
unfolded protein response (UPR) [11,18,35]. COMP and other
ECM proteins accumulate in the ER associated with numerous
chaperone proteins, including CRT, protein disulfide isomerase,
Grp94 and BiP [24]. Deconvolution analysis showed that the
protein retained in the rER of PSACH chondrocytes is organized
into an ordered intracellular matrix and this may hinder the ER
clearance mechanisms [9,10]. Prolonged stress due to protein
accumulation in the rER ultimately causes premature chondrocyte
cell death [11,13,37,38]. Surprisingly, mice lacking COMP have
only minor skeletal anomalies, suggesting that absence of COMP
is not detrimental to morphogenesis and skeletal development
[16]. It is the disparity between the human PSACH phenotype
and COMP null mouse phenotype that led us to investigate RNAi
as a potential therapy for COMP-related skeletal dysplasias by
eliminating all COMP mRNA.
RNAi therapies are being tested in a variety of condi-
tions including, cancer, macular degeneration, movement
disorders, heart failure, storage diseases, prion disease,
viral infection, chronic pain and addictive-induced behavior
[5,39,40,41,42,43,44,45,46,47,48,49,50,51,52]. Vascular endothe-
lial growth factor (VEGF)-targeted siRNA therapies for age related
wet type of macular degeneration are the closest to clinical
application and have progressed to safety and efficacy clinical trials
[53,54]. Age-related wet type of macular degeneration occurs
when excess blood vessels behind the retina interfere with vision.
Figure 5. shRNA knockdown was maintained in the presence of
high levels of COMP. COS-7 cells with and without 3B shRNA
integrant were infected with a DOX-inducible MT-COMP adenovirus.
DOX dosage ranging from 1 ng/ml to 10 mg/ml was used. Protein lysate
was collected 48 hours after adenovirus infection. (A) Western blot
analysis of COMP expression in the absence of shRNA 3B. (B) Western
blot analysis of COMP expression in the presence of shRNA 3B.
doi:10.1371/journal.pone.0010302.g005
Figure 6. shRNAs directed against human COMP reduces
steady-state levels of endogenous COMP mRNA from primary
chondrocytes. A population of integrants for each shRNA was isolated
using puromycin selection as described in the Methods section. Primary
human chondrocytes, with and without an shRNA, were cultured in
monolayer for one week and RNA was collected. COMP is expressed in
primary human chondrocytes grown in monolayer culture. qRT-PCR was
used to quantify the COMP mRNA levels and b-actin mRNA levels were
used to normalize the RNA.
doi:10.1371/journal.pone.0010302.g006
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Blood vessel growth suppression by silencing of VEGF expression
has been shown to improve vision [42], For Gaucher disease, a
lysosomal storage disorder, RNAi substrate reduction therapy also
shows promise [48]. The therapeutic approach taken in Gaucher
cells is to diminish the amount of substrate processed through the
lysosome so that the remaining substrate can be cleared by the
residual lysosomal enzyme activity [48]. Using a similar approach,
we postulated that COMP reduction therapy would decrease the
load of improperly folded COMP in the rER, thereby preventing
intracellular protein accumulation and subsequent ER stress.
The PSACH and MED/EDM1 cellular pathology occurs
for the first 15–18 years which coincides with human skeletal
growth [2,17,18]. Therefore, long-term knock down of COMP
is necessary to suppress PSACH and MED/EDM1 cellular
phenotype. In non-dividing cells, exogenously introduced siRNAs
are degraded within a few weeks and in dividing cells, siRNAs are
diluted to non-effective concentrations within 3–7 days after
transfection [54]. In contrast, shRNAs have been shown to reduce
target mRNA for longer periods (up to 51 days) [55,56]. In these
studies, using the COS-7 culture system, long-term decreases in
COMP expression were sustainable for up to two weeks in the
presence of recombinant COMP (Fig. 4). In human chondrocytes
with shRNA integrants, COMP suppression was maintained up to
ten weeks (data not shown). These results suggest that long-term
suppression is possible using shRNAs directed against COMP.
COMP is expressed at high levels during skeletal development
and long bone growth and therefore it is important that RNAi
therapy be capable of reducing high expression levels of COMP
[2,17,18]. Using a DOX-inducible system, we tested shRNA 3B
against varying levels of COMP expression. Knock down was
observed with all levels of COMP expression suggesting that
shRNA 3B was effective even when target mRNA levels are high
and therapeutic intervention would be most needed (Fig. 5).
We also demonstrated in RCS cells that shRNA 3B efficiently
reduced intracellular retention of MT-COMP, MATN3 and type
IX collagen, thereby preventing the development of intracellular
matrix that defines the PSACH and MED/EDM1 cellular
phenotype. Moreover, in both COS-7 and RCS cells, shRNA
3B reduced the elevated CRT levels that result from the
overexpression of COMP. Taken together, these results suggest
that reducing mutant COMP mRNA levels may dampen the ER
stress and matrix formation in the rER that is potentiated by the
presence of mutant COMP.
Overall, we show that suppression of COMP expression by
RNAi in vitro would be an effective treatment modality for the
PSACH and MED/EDM1 chondrocyte pathology. This work
provides a proof of principle for the potential development of
treatment for this ER storage disorder. Delivery of RNAi therapy
to avascular tissues, such as cartilage may be a challenge. In one
approach, the delivery of siRNA molecules to bone metastatic
Figure 7. Immunohistochemistry analysis of RCS cells expressing MT-COMP with and without a COMP-directed shRNA 3B. RCS cells
with (right panel) and without (left panel) shRNA 3B, grown on coverslips, were infected with adenovirus expressing MT-COMP-FLAG and GFP. Cells
were fixed 4 days after adenoviral infection and immunostained with COMP, type IX collagen, MATN3 and type II collagen antibodies as described in
the Methods section. GFP was used to identify infected cells. FLAG was used as a marker for recombinant COMP (red) and the rER was delineated with
a CRT antibody (blue).
doi:10.1371/journal.pone.0010302.g007
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tumors was mediated by their attachment to bovine pepsin treated
type I collagen (atelocollagen) [57,58]. This complex was infused
and taken up by the tumor. Future delivery mechanisms that
target cartilaginous tissue and/or chondrocytes need to be
developed. The long-term goal for a treatment modality for
PSACH and MED/EDM1 is to prevent premature chondrocyte
loss and restore chondrocyte function, which is necessary for
normal bone growth and ECM integrity.
Materials and Methods
shRNA expression cassettes and recombinant shRNA
lentivirus
shRNA lentiviral particles that target human COMP were
purchased from the MISSIONH TRC-Hs 1.0 (Human) (Sigma, St.
Louis, Missouri). MISSION shRNA clones were designed and
developed by The RNAi Consortium (TRC) at the Broad Institute
of MIT and Harvard University. Each shRNA is a hairpin with 21
base pair long stem and a 6 nucleotide loop. Expression of the
shRNA is driven by the U6 promoter. The target region of
each shRNA is shown in Figure 1. Target sequences are: 3A
CCCAGAAGAACGACGACCAAA, 3B ATGCTTGTGACAG-
CGATCAAC, GA TGTGGGTTACACTGCCTTCAA and GB
CAAACGTATTGGCAGGCGAAC.
Design and generation of a GFP reporter COMP
adenovirus
The bicistronic constructs were designed to express MT- or
WT-COMP with a FLAG tag moiety (DYKDDDDK) at the
carboxy terminus and GFP reporter gene under the control of the
cytomegalovirus (CMV) promoter. The D469del mutation, used in
this study, is the most common PSACH mutation accounting for
approximately 30% of cases [34]. These constructs and viruses
were previously used in our PSACH cell culture model system [9].
Using the AdEasy vector system kit (Qbiogene, Irvine, CA) and
following manufacturer’s guidelines, the expression cassettes were
then placed into a replication-defective recombinant adenovirus
vector. All constructs were verified by sequencing.
Design and generation of an inducible recombinant
COMP adenovirus
Inducible WT- and MT-COMP expression cassettes were
designed so that the level of COMP expression could be
modulated by altering DOX concentration in the culture medium.
Two subcloning steps were performed to generate the final vector
pShuttle-TRE-COMP-CMV-rtTA. First, the CMV-rtTA cassette
from pTet-On (Clontech, Mountain View, CA) was inserted into
the pShuttle (Stratagene, La Jolla, CA) using PCR (59CCAGT-
CACGTAGCGATAGCGGAGTG39 For and 59ATAGATC-
TAAGCTTGGTCGAGCTGATACTTCCCG 39 Rev) and di-
gested with Xho I and Bgl II. The resulting fragment was ligated
into complementary sites in pShuttle (Sal I and Bgl II) (Stratagene,
La Jolla, CA). Next, the WT- or MT-COMP-FLAG gene driven
by the tetracycline responsive element (TRE) was inserted into
pShuttle-CMV-rtTA to produce the final construct pShuttle-TRE-
COMP-CMV-rtTA. All constructs were verified by sequencing.
The AdEasy vector system kit (Qbiogene, Irvine, CA) was again
used as described above. Recombinant adenovirus were subse-
quently produced, isolated and quantified.
Cell culture techniques
COS-7 (Sigma, St. Louis, Missouri) and RCS [59] cells were
cultured in DMEM with 10% FBS and antibiotics and passaged
until 80% confluent using standard methods. Primary human
costochondral chondrocytes were collected from patients under-
going pectus excavatum surgery and obtained from the Iowa
Skeletal Dysplasia Cell Bank with IRB approval. These cells were
cultured using standard conditions in DMEM with 20% v/v FBS
as previously described [36].
Generation of cells expressing shRNA
Lentivirus particles containing a shRNA were used to infect
RCS and COS-7 cells at multiplicity of infection (MOI) of 0.1 to
insure that single colonies of integrants could be isolated. Cells
were cultured for three days in non-selective media and puromycin
was then added to select stable integrants. Single colonies were
moved to separate dishes and grown in standard culture media
with puromycin for these experiments. Primary human costo-
chondral chondrocytes were infected at MOI of 1 with shRNA
lentiviruses and grown for five days in non-selective media and
then in puromycin to select cell populations that contained an
shRNA. All human primary chondrocytes in these experiments are
from a population of shRNA integrants.
Transfection of cells with recombinant adenoviruses
COS-7 cells with and without an shRNA integrant were
cultured until 70–80% confluent and infected with either the WT-
or MT-COMP-GFP or DOX inducible WT- or MT-COMP-
FLAG adenovirus (MOI 15 for all adenovirus infections) in
DMEM with 2% v/v FBS. Cells were harvested 48 hrs later or at
time points required for the experiments. RCS cells with and
without a shRNA integrant were plated on to coverslips and
24 hrs later treated with 1 mg/ml hyaluronidase for 1 hour at
37uC and then infected with MT-COMP-FLAG (GFP) adenovirus
(MOI 400–800) in OPTI-MEM media (Gibco, Carlsbad, CA).
mRNA and protein analyses
Northern and Western analyses were used to assess mRNA and
proteins in all experiments using standard techniques. Sample
loading in Northern and Western analyses was normalized using
Snu-6 and b-actin, respectively. Westerns were performed using
anti-COMP rabbit polyclonal antibody (Kamiya, Thousand Oaks,
CA) and detected using ECL Plus (GE Healthcare Biosciences,
Pittsburgh, PA).
Histology and immunohistochemistry
RCS cells and COS-7 cells were grown on coverslips and fixed
using 4% v/v paraformaldehyde after 4 days and 100% methanol
after 2 days, respectively, at 4uC for 20 min. All coverslips were
incubated overnight at 4uC with the primary antibodies (1:200).
Table 1 lists the antibodies used in this study. Primary antibodies
were detected using fluorochrome conjugated secondary antibod-
ies (1:400) (Table 1). Co-immunostaining and imaging was
performed as previously described and all exposure times are
equal [9,10]. Coverslips were mounted using ProLong Gold anti-
fade reagent (Molecular Probes, Carlsbad, CA) or DAPI (49-6-
Diamidino-2-phenylindole) prolong gold anti-fade reagent staining
to detect nuclei.
Quantitative real-time RT-PCR
RNA from chondrocytes with and without an shRNA integrant
was collected for RT-PCR assays after one week in culture.
Quantitative real-time RT-PCR (qRT-PCR) was performed
utilizing the 7700 Sequence Detector (Applied Biosystems, Foster
City, CA). DNA contamination was removed using amplification
grade DNAse (Invitrogen, Carlsbad, CA) following manufacturer’s
RNAi Reduces COMP
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instructions. Each assay was replicated three times and each
sample was measured in triplicate including a control without
reverse transcriptase. The final data were normalized to b-actin6
100 (percent of the normalizer transcript).
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